Studie - Cervical Dysplasia – Pipeline Review, H1 2012

Cervical Dysplasia — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Cervical Dysplasia - Pipeline Review, H1 2012', provides an overview of the Cervical Dysplasia therapeutic pipeline. This report provides information on the therapeutic development for Cervical Dysplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Dysplasia. 'Cervical Dysplasia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Cervical Dysplasia.
- A review of the Cervical Dysplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cervical Dysplasia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cervical Dysplasia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cervical Dysplasia pipeline depth and focus of Cervical Dysplasia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Cervical Dysplasia Overview 6

Therapeutics Development 7

An Overview of Pipeline Products for Cervical Dysplasia 7

Cervical Dysplasia Therapeutics under Development by Companies 9

Cervical Dysplasia Therapeutics under Investigation by Universities/Institutes 10

Late Stage Products 11

Comparative Analysis 11

Mid Clinical Stage Products 12

Comparative Analysis 12

Early Clinical Stage Products 13

Comparative Analysis 13

Cervical Dysplasia Therapeutics — Products under Development by Companies 14

Cervical Dysplasia Therapeutics — Products under Investigation by Universities/Institutes 15

Companies Involved in Cervical Dysplasia Therapeutics Development 16

Inovio Biomedical Corporation 16

Advaxis, Inc. 17

N.V. Mithra Pharmaceuticals S.A. 18

Cervical Dysplasia — Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Combination Products 20

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Drug Profiles 25

VGX-3100 - Drug Profile 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

ADXS-HPV - Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Imiquimod - Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Curcumin - Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Fenretinide - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Cidofovir Gel - Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

SGN-00101 - Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

TA-HPV + Detox + Imiquimod - Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Cervical Dysplasia Therapeutics — Drug Profile Updates 35

Cervical Dysplasia Therapeutics — Discontinued Products 38

Cervical Dysplasia Therapeutics - Dormant Products 39

Cervical Dysplasia — Product Development Milestones 40

Featured News & Press Releases 40

Nov 11, 2011: FDA Removes Clinical Hold For Helix's Topical Interferon Alpha-2b Phase II/III Efficacy Trial IND Application 40

Oct 31, 2011: Fierce Vaccines Highlights Inovio's Cervical Dysplasia And Cancer Vaccine As One Of 10 Promising Therapeutic Vaccines 41

Oct 05, 2011: Inovio's Synthetic Vaccine For Cancer Recognized As Most Promising Research At Global Vaccine Congress 41

Jul 15, 2011: Inovio Demonstrates T Cell Immune Response From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine 42

May 09, 2011: Inovio Reports Long-Term Immune Responses From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine 43

Jan 14, 2011: Advaxis Wins Approval To Complete Dosing In First Leg Of Phase II Cervical Dysplasia Trial 44

Oct 21, 2010: Advaxis Completes Recruitment Of First 11 Patients In US Cervical Dysplasia Study 44

Sep 22, 2010: Advaxis Receives Indian Approval For Cervix Cancer Trial 45

May 28, 2010: Advaxis Doses First Patient In Phase II Cervical Dysplasia Trial 46

Apr 15, 2010: Adavaxis Opens First Trial Site In Phase II Clinical Trial Of ADXS11-001 46

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 49

Disclaimer 49





List of Tables

Number of Products Under Development for Cervical Dysplasia, H1 2012 7

Products under Development for Cervical Dysplasia — Comparative Analysis, H1 2012 8

Number of Products under Development by Companies, H1 2012 9

Number of Products under Investigation by Universities/Institutes, H1 2012 10

Comparative Analysis by Late Stage Development, H1 2012 11

Comparative Analysis by Mid Clinical Stage Development, H1 2012 12

Comparative Analysis by Early Clinical Stage Development, H1 2012 13

Products under Development by Companies, H1 2012 14

Products under Investigation by Universities/Institutes, H1 2012 15

Inovio Biomedical Corporation, H1 2012 16

Advaxis, Inc., H1 2012 17

N.V. Mithra Pharmaceuticals S.A., H1 2012 18

Assessment by Monotherapy Products, H1 2012 19

Assessment by Combination Products, H1 2012 20

Assessment by Stage and Route of Administration, H1 2012 22

Assessment by Stage and Molecule Type, H1 2012 24

Cervical Dysplasia Therapeutics — Drug Profile Updates 35

Cervical Dysplasia Therapeutics — Discontinued Products 38

Cervical Dysplasia Therapeutics — Dormant Products 39





List of Figures

Number of Products under Development for Cervical Dysplasia, H1 2012 7

Products under Development for Cervical Dysplasia — Comparative Analysis, H1 2012 8

Products under Development by Companies, H1 2012 9

Products under Investigation by Universities/Institutes, H1 2012 10

Late Stage Products, H1 2012 11

Mid Clinical Stage Products, H1 2012 12

Early Clinical Stage Products, H1 2012 13

Assessment by Monotherapy Products, H1 2012 19

Assessment by Combination Products, H1 2012 20

Assessment by Route of Administration, H1 2012 21

Assessment by Stage and Route of Administration, H1 2012 22

Assessment by Molecule Type, H1 2012 23

Assessment by Stage and Molecule Type, H1 2012 24

• Acute Inflammation – Pipeline Review, H1 2013
• Ovarian Disease – Pipeline Review, H1 2013
• Premenstrual Syndrome – Pipeline Review, H1 2013
• Female Hypoactive Sexual Desire Disorder – Pipeline Review, H1 2013
• Cervical Dysplasia – Pipeline Review, H1 2013
• EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
• Female Sexual Dysfunction – Pipeline Review, H1 2013
• Menopausal Disorders – Pipeline Review, H1 2013
• Menopausal Hot Flashes – Pipeline Review, H1 2013
• Uterine Fibroids – Pipeline Review, H1 2013
• Vaginal Atrophy (Atrophic Vaginitis) – Pipeline Review, H1 2013
• Contraceptives – Pipeline Review, H1 2013
• Dysmenorrhea – Pipeline Review, H1 2013
• Endometriosis – Pipeline Review, H1 2013
• Women Infertility – Pipeline Review, H1 2013
• Premature Labor (Tocolysis) – Pipeline Review, H2 2012
• Vasomotor Symptoms of Menopause – Pipeline Review, H2 2012
• Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen
• Premature Ovarian Failure – Pipeline Review, H2 2012
• Premenstrual Syndrome – Pipeline Review, H2 2012